CHM-0201 is under clinical development by Chimeric Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CHM-0201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CHM-0201 is under development for the treatment of relapsed/refractory hematological malignancies such as refractory acute myeloid leukemia(AML), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma(NHL), Hodgkin's lymphoma (HL), myeloproliferative neoplasms (MPN), plasma cell myeloma and locally advanced or metastatic colorectal carcinoma, relapsed/refractory soft tissue carcinomas. The therapeutic candidate comprises allogenic natural killer (NK) cells. It is administered through parenteral route. It is being developed based on CORE-NK technology platform.
Chimeric Therapeutics overview
Chimeric Therapeutics is a clinical stage cell therapy company that discovers and develops therapies for treatment of cancer. The company focuses on development of cell based allogenic and autologous therapies. It is investigating CHM1301 and CHM 2301 programs against solid tumors; CHM 0301, to treat blood cancer; and CHM 0201, for hematological malignancies disorder and solid tumors. Chimeric Therapeutics is also developing chimeric antigen receptor (CAR) T cell-based therapies such as CHM 1101 program for treatment of glioblastoma, melanoma and colorectal cancer; and CHM 2101 against Neuroendocrine cancer. Chimeric Therapeutics is headquartered in Carlton, Victoria, Australia.
For a complete picture of CHM-0201’s drug-specific PTSR and LoA scores, buy the report here.